Republican lawmakers urged the Trump administration and the FDA to preserve or strengthen requirements aimed at ensuring clinical trials enroll diverse populations. The push comes as clinical trial policy is intertwined with broader administration moves that removed references to DEI from parts of the HHS ecosystem. Supporters of trial diversity argue the focus is not about hiring or communications DEI definitions, but about enrolling patient-representative populations to improve whether drugs and devices perform in the real-world groups that use them. The reporting describes lawmakers’ concern that diversity-enrollment priorities could be diluted during the policy reset, leaving enrollment practices less aligned with clinical populations. For sponsors, the development increases pressure to anticipate regulator and legislative scrutiny on study design, inclusion criteria, site selection, and enrollment monitoring—elements that can affect timelines, costs, and label breadth.